Cellromax Science Co., Ltd.

471820· KOSDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences

₩4,065+0.25%

2026-08-04

Financials

Valuation Metrics

Cellromax Science Co., Ltd.'s Market Cap is ₩459B. At end of 2025 it was ₩735B. Ranked #1776 of 2,436 in KR market (top 73%), #1076 of 1,649 on KOSDAQ (top 65%), #193 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 82%) by Market Cap.

Investment Metrics(as of 2026-08-04)

Metric	Value	Rank
Size
Market Cap	45.95B KRW	KR#1,776/2,436 Sec#193/234
Revenue	20.98B KRW	KR#2,127/2,436 Sec#153/234
Net Income	2.65B KRW	KR#1,298/2,436 Sec#90/234
Total Assets	52.02B KRW	KR#2,171/2,436 Sec#195/234
Net Assets	47.63B KRW	KR#1,910/2,436 Sec#165/234
Value
P/E	17.33x	KR#1,061/2,436 Sec#64/234
P/B	0.96x	KR#1,488/2,436 Sec#98/234
P/S	2.19x	KR#1,899/2,436 Sec#110/234
EV/EBITDA	18.34x	KR#975/2,436 Sec#56/234
FCF Yield	3.71%	KR#961/2,436 Sec#57/234
Profitability
ROE	5.57%	KR#929/2,436 Sec#70/234
ROA	5.10%	KR#639/2,436 Sec#50/234
Op. Margin	11.11%	KR#427/2,436 Sec#39/234
Revenue Growth	-20.42%	KR#2,072/2,436 Sec#188/234
Earnings Growth	-30.54%	KR#1,111/2,436 Sec#71/234
Financial Health
Debt Ratio	9.23%	KR#10/2,436 Sec#4/234
FCF	1.71B KRW	KR#1,102/2,436 Sec#80/234
Cash	3.21B KRW	KR#2,136/2,436 Sec#200/234
Current Ratio	4.87x	KR#303/2,436 Sec#57/234
Net Debt/EBITDA	-1.38x	KR#390/2,436 Sec#20/234
Dividend
Div. Yield	4.56%	KR#346/2,436 Sec#11/234
Div. Growth	12.12%	KR#544/2,436 Sec#30/234
Performance
1Y Return	-30.15%	KR#1,516/2,436 Sec#131/234
1M Return	-9.36%	KR#1,486/2,436 Sec#140/234
From 52W High	-47.14%	KR#987/2,436 Sec#77/234
1Y MDD	-46.78%	KR#779/2,436 Sec#66/234
Trading
Volume	8,512 shares	KR#2,339/2,436 Sec#230/234
Foreign Own.	1.42%	KR—/2,436 Sec—/234
Per Share
EPS	293 KRW	KR#1,101/2,436 Sec#75/234
BPS	4,266 KRW	KR#1,569/2,436 Sec#118/234